Skip to main content
SpringerLink
Log in

Clinical Importance of Prognostic Factors

Moving from Scientifically Interesting to Clinically Useful

  • Chapter
Principles of Molecular Oncology

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. ASCO Expert Panel. Clinical Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer: Report of the American Society of Clinical Oncology Expert Panel. J Clin Oncol. 1996;14:2843–2877.

    Google Scholar 

  2. ASCO Expert Panel. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 1998;16:793–795.

    Google Scholar 

  3. 3. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19:1865–1878.

    PubMed  Google Scholar 

  4. 4. Bast RC Jr., Ravdin P, Hayes DF, et al. Errata:2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:4185–4188.

    Google Scholar 

  5. 5. Hayes DF, Bast R, Desch CE, et al. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456–1466.

    Article  PubMed  CAS  Google Scholar 

  6. 6. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–9072.

    Article  PubMed  Google Scholar 

  7. 7. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000;355:1822.

    Article  PubMed  CAS  Google Scholar 

  8. 8. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–1792.

    Article  PubMed  CAS  Google Scholar 

  9. Early Breast Cancer Trialists Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet. 1996;348:1189–1196.

    Google Scholar 

  10. Early Breast Cancer Trialist’s Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 1998;351:1451–1467.

    Google Scholar 

  11. Early Breast Cancer Trialist’s Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet. 1998;352:930–942.

    Google Scholar 

  12. Early Breast Cancer Trialist’s Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717.

    Google Scholar 

  13. 13. Ellis M, Hayes DF, Lippman ME. Treatment of metastatic disease. In: Harris J, Lippman M, Morrow M, Osborne CK, eds. Diseases of the breast. 2nd ed. Philadelphia: Lippincott-Raven; 2000:749–798.

    Google Scholar 

  14. 14. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388.

    Article  PubMed  CAS  Google Scholar 

  15. 15. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol. 2005;23:619–629.

    Article  PubMed  CAS  Google Scholar 

  16. 16. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med. 1992;326:1756–1761.

    Article  PubMed  CAS  Google Scholar 

  17. 17. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst. 1993;85:1206–1219.

    Article  PubMed  CAS  Google Scholar 

  18. AJCC. Cancer staging manual. In: Greene FL, Page DL, Fleming I, et al., eds. American Joint Committee on Cancer, Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.

    Google Scholar 

  19. 19. Osborne CK. Receptors. In: Harris J, Hellman S, Henderson I, Kinne D, eds. Breast diseases. 2nd ed. Philadelphia: J.B. Lippincott; 1991:301–325.

    Google Scholar 

  20. 20. Trock B, Leonessa F, Clarke R. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997;89:917–931.

    Article  PubMed  CAS  Google Scholar 

  21. 21. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–484.

    Article  PubMed  CAS  Google Scholar 

  22. 22. Fisher B, Redmond C, Dimitrov N, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989;320:473–478.

    Article  PubMed  CAS  Google Scholar 

  23. 23. Ravdin PM. Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 1999;26(4 Suppl 12):117–123.

    PubMed  CAS  Google Scholar 

  24. 24. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894–2904.

    PubMed  CAS  Google Scholar 

  25. 25. Hayes DF. Tumor markers for breast cancer. Ann Oncol. 1993;4:807–819.

    PubMed  CAS  Google Scholar 

  26. 26. Trock BJ, Yamauchi H, Brotzman M, Stearns V, Hayes DF. c-erbB-2 as a prognostic factor in breast cancer: A meta-analysis. Proc Am Soc Clin Oncol. 2000;372:97.

    Google Scholar 

  27. 27. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808–3816.

    PubMed  CAS  Google Scholar 

  28. 28. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334–2356.

    PubMed  CAS  Google Scholar 

  29. 29. Muss HB, Thor A, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260–1266.

    Article  PubMed  CAS  Google Scholar 

  30. 30. Thor A, Berry D, Budman D, et al. erbB2, p53, and adjuvant therapy interactions in node positive breast cancer. J Natl Cancer Inst. 1998;90:1346–1360.

    Article  PubMed  CAS  Google Scholar 

  31. 31. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med, 2006;354:2103–2111.

    Article  CAS  Google Scholar 

  32. 32. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.

    Article  PubMed  CAS  Google Scholar 

  33. 33. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol. 2000;27(6 Suppl 11):46–52; discussion 92–100.

    PubMed  CAS  Google Scholar 

  34. 34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.

    Article  PubMed  CAS  Google Scholar 

  35. 35. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684.

    Article  PubMed  CAS  Google Scholar 

  36. 36. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–820.

    Article  PubMed  CAS  Google Scholar 

  37. 37. Coates AS, Simes RJ. Patient assessment of adjuvant treatment in operable breast cancer. In: Williams CJ, ed. Introducing new treatments for cancer: Practical, ethical, and legal problems. New York, NY: John Wiley; 1992:447–458.

    Google Scholar 

  38. 38. Ravdin P, Siminoff I, Harvey J. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol. 1998;16:515–521.

    PubMed  CAS  Google Scholar 

  39. 39. Lindley C, Vasa S, Sawyer T, Winer E. Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer. J Clin Oncol. 1998;16:1380–1387.

    PubMed  CAS  Google Scholar 

  40. 40. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980–991.

    PubMed  CAS  Google Scholar 

  41. 41. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol. 2001;19:972–999.

    PubMed  CAS  Google Scholar 

  42. 42. Whelan TJ, Loprinzi C. Physician/patient decision aids for adjuvant therapy. J Clin Oncol. 2005;23:1627–1630.

    Article  PubMed  Google Scholar 

  43. 43. Hayes DF, Trock B, Harris A. Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful? Breast Cancer Res Treat. 1998;52:305–319.

    Article  PubMed  CAS  Google Scholar 

  44. 44. Isaacs C, Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence. Semin Oncol. 2001;28:53–67.

    Article  PubMed  CAS  Google Scholar 

  45. 45. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: Current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001;6:375–392.

    Article  PubMed  CAS  Google Scholar 

  46. 46. Hayes DF. Do we need prognostic factors in nodal-negative breast cancer? Arbiter. Eur J Cancer. 2000;36:302–306.

    Article  PubMed  CAS  Google Scholar 

  47. 47. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240–246.

    Article  PubMed  Google Scholar 

  48. 48. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685.

    PubMed  CAS  Google Scholar 

  49. 49. Simon R. Design and analysis of clinical trials. In: DeVita J, VT, Hellman S, Rosenberg S, eds. Cancer: Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001:521–538.

    Google Scholar 

  50. 50. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer, 2005;5: 142–149.

    Article  CAS  Google Scholar 

  51. 51. Hayes DF. Determination of clinical utility of tumor markers: a tumor marker utility grading system. Recent Results Cancer Res. 1998;152:71–85.

    PubMed  CAS  Google Scholar 

  52. 52. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983.

    Article  PubMed  CAS  Google Scholar 

  53. 53. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–3696.

    Article  PubMed  CAS  Google Scholar 

  54. 54. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658–1667.

    Article  PubMed  CAS  Google Scholar 

  55. 55. Paik S, Shak S, Tang G, et al. A multi-gene RT-PCR assay using fixed, paraffin-embedded tumor tissue to predict the likelihood of breast cancer recurrence in node negative, estrogen receptor positive, tamoxifen-treated patients. N Engl J Med. 2004;351:2817–2826.

    Article  PubMed  CAS  Google Scholar 

  56. 56. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734.

    Article  PubMed  CAS  Google Scholar 

  57. 57. Strauss GM, Skarin AT. Use of tumor markers in lung cancer. In: Hayes DF, ed. Hematology/oncology clinics of North America: Tumor markers in adult solid malignancies. Philadelphia: WB Saunders; 1994:507–532.

    Google Scholar 

  58. 58. Kantoff PW, Talcott JA. The prostate specific antigen: Its use as a tumor marker for prostate cancer. In: Hayes DF, ed. Hematology/oncology clinics of North America: Tumor markers in adult solid malignancies. Philadelphia: WB Saunders; 1994:555–572.

    Google Scholar 

  59. 59. Ozols R, Schwartz P, Eifel P. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinma. In: DeVita V, Hellman S, Rosenburg S, eds. Cancer: Principles and practice of oncology. 5th ed. Philadelphia, New York: Lippincott-Raven; 1997:1502–1539.

    Google Scholar 

  60. 60. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem. 1998;44:1379–1380.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA

    N. Lynn Henry MD, PhD

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA

    Daniel F. Hayes MD

Authors
  1. N. Lynn Henry MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel F. Hayes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hospital General of Granollers, Barcelona, Spain

    Miguel H. Bronchud MD, PhD

  2. MA Foote Associates, Westlake Village, CA, USA

    Mary Ann Foote PhD

  3. National Cancer Institute, Bethesda, Maryland

    Giuseppe Giaccone MD, PhD

  4. University of Chicago Medical Center, Chicago, IL, USA

    Olufunmilayo Olopade MD

  5. CRC Center for Cancer Therapeutics, Surrey, UK

    Paul Workman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc.

About this chapter

Cite this chapter

Henry, N.L., Hayes, D.F. (2008). Clinical Importance of Prognostic Factors. In: Bronchud, M.H., Foote, M.A., Giaccone, G., Olopade, O., Workman, P. (eds) Principles of Molecular Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-470-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-470-4_2

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-25-1

  • Online ISBN: 978-1-59745-470-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation